Olympus Partners reported on Wednesday the completion of the divestiture of The Ritedose Corporation for an undisclosed amount.

Ritedose, a leading manufacturer of respiratory and ophthalmic drugs, is the foremost pharmaceutical manufacturer utilising "blow-fill-seal" technology, where a container is formed, filled and sealed in a continuous, highly automated process inside a sterile enclosed machine in a "clean room" facility.

Since Ritedose's acquisition in 2009, the company has grown to the second largest generic respiratory player, launched its own generic pharmaceutical brand, increased production capacity by 80% and expanded into new therapeutic categories such as dry eye.

Founded in 1988, Olympus Partners is a private equity firm focused on providing equity capital for management buyouts and for companies needing capital for expansion.

In the sale, Ritedose was represented by William Blair and Robert W. Baird with legal representation from Kirkland & Ellis.